Axsome Therapeutics (AXSM) shares ended the last trading session 11.5% higher at $89.27. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.2% loss over the past four weeks.The stock rallied after the company announced robust preliminary net product revenues for its marketed drugs, Auvelity and Sunosi, for the fourth quarter and full year 2024. Auvelity sales in the fourth quarter of 2024 are expected to be around ...

公司基本信息 - 公司注册地为特拉华州，总部位于纽约市[2] - 公司普通股在纳斯达克全球市场交易，股票代码为AXSM[5] - 公司总裁兼首席执行官为Herriot Tabuteau, M.D.[12] 财务报告与披露 - 公司发布了2024年第四季度和全年净收入的初步报告[6] - 公司通过8-K表格提交了2025年1月13日的新闻稿作为附件99.1[6] - 新闻稿的全文被纳入8-K表格的8.01项中[7] - 公司未在8-K表格中提交任何新的财务报表[8] 公司发展与战略 - 公司未报告任何新的并购或市场扩张计划[6][7] - 公司未提及新产品或新技术的研发进展[6][7] 公司治理与合规 - 公司未选择使用新兴成长公司的延长过渡期[5]

Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi preliminary 4Q and full year 2024 net product revenue of $25.7 million and $93.8 million, respectively NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced preliminary net product revenue for the fourth quarter and full year ended December ...

ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) ACCORD-2 Phase 3 trial achieves key secondary endpoint compared to placebo (p=0.001, prevention of relapse of Alzheimer’s disease agitation) AXS-05 reduced worsening of Alzheimer’s disease overall compared to placebo in ACCORD-2 Phase 3 trial (p<0.001, CGI-S Alzheimer’s disease overall clinical status) ADVANCE-2 trial did not demonstrate statistical significance on primary endpoin ...

It has been about a month since the last earnings report for Axsome Therapeutics (AXSM) . Shares have lost about 0.1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Axsome due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Axsome's Q3 Earnings Beat, Auvelity Drives ...

Axsome Therapeutics, Inc. (AXSM) incurred an adjusted loss of $1.34 per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $1.38. The company had incurred a loss of $1.32 per share in the year-ago quarter.Axsome’s total revenues surged 81% year over year to $104.8 million in the third quarter, beating the Zacks Consensus Estimate of $99 million. The increase in revenues can be attributed to strong sales of Auvelity (AXS-05).Shares of Axsome were up 9.4% on Nov. 12 ow ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - EVP and Head, Commercial Mark Jacobson - Chief Operating Officer Conference Call Participants Jason Gerberry - Bank of America Leonid Timashev - RBC Capital Markets Charles Duncan - Cantor Fitzgerald Cerena Chen - Wells Fargo David Amsellem - Piper Sandler Marc Goodman - Leerink Part ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-37635 AXSOME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45- ...

Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.38. This compares to loss of $1.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.90%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.30 per share when it actually produced a loss of $1.24, delivering a surprise of 4.62%.Over the last four quarters, the ...

业绩总结 - 2024年第三季度总净产品收入为1.048亿美元，同比增长81%[17] - 2024年第三季度净产品销售额为8040万美元，同比增长113%[81] - 2024年第三季度Sunosi的净产品收入为2440万美元，同比增长21%[82] - Auvelity的销售额在2024年第三季度达到8040万美元，创下历史新高[88] - Sunosi在2024年第三季度的销售额为2440万美元，显示出稳定的市场需求[90] 用户数据 - Auvelity的销售额中，约有140,000名新患者和超过28,000名独特开处方医生自上市以来[81] - Sunosi的销售中，超过76,000名新患者和超过13,000名独特开处方医生自初次上市以来[82] - Auvelity的处方中，50%的处方来自于一线或二线用药[81] - Sunosi的患者满意度高，主要原因包括副作用少或没有副作用[82] - Auvelity的覆盖人群中，78%为商业和政府渠道的受保人群[81] - Sunosi的覆盖人群中，83%为商业和政府渠道的受保人群[82] 未来展望 - 预计到2025/2026年将获得至少3项FDA批准，并在2027年前推出7个新产品/适应症[14] - AXS-07的PDUFA目标日期为2025年1月31日[16] - 预计AXS-14在纤维肌痛症的NDA提交预计在2024年11月[21] - 预计AXS-12在嗜睡症的ENCORE三期试验结果将在2024年第四季度公布[40] - 预计AXS-05在阿尔茨海默病激动症的ADVANCE-2三期试验结果将在2024年第四季度公布[30] - 预计AXS-05在重度抑郁症的FOCUS三期试验结果将在2025年第一季度公布[39] - 预计AXS-07在偏头痛的NDA重新提交将于2025年1月进行[79] - 预计Solriamfetol在注意力缺陷多动障碍的PARADIGM三期试验结果将在2025年第一季度公布[53] 新产品和新技术研发 - AXS-07在MOMENTUM Phase 3临床试验中，1594名患者显示出显著的疼痛缓解效果[27] - AXS-12在SYMPHONY Phase 3试验中，显示出对比安慰剂有统计学显著的猫癫痫发作减少（p<0.001）[123] - 预计2025年第一季度发布AXS-12在嗜睡症中的顶线数据[126] - 预计2025年第一季度发布solriamfetol在注意力缺陷多动障碍（ADHD）中的顶线数据[138] 市场扩张和并购 - Axsome Therapeutics的现金余额为3.273亿美元，债务面值为1.8亿美元，市值为44亿美元[165] - Axsome Therapeutics拥有超过98项已授予的美国专利和超过129项已授予的国际专利，专利保护延续至2043年[163] 负面信息 - 超过70%的偏头痛患者对当前治疗不满意，渴望更快、更持久的疗法[26] - 超过70%的重度抑郁症患者在一线标准治疗中仅部分改善症状[148] - 在美国，约有700万人患有暴食症（BED），该病在女性中比男性更常见，比例为1.75倍[154] - 在美国，约有1500万工人可能患有轮班工作障碍（SWD），该病与多种健康问题相关[159]